Tokyo Tape
Sign in
← Otsuka Holdings

Half-year report · Q2

4578.TEDINET S100WFZ0
Period2025-01-01 → 2025-06-30
Filed2025-07-31
StandardIFRS
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 44
MetricValuePeriodScopeSource row
Revenue¥1.18T2025-01-01 → 2025-06-30Cons.Revenue IFRS
Revenue¥2.33T2024-01-01 → 2024-12-31Cons.Revenue IFRS (5-year summary)
Revenue¥1.11T2024-01-01 → 2024-06-30Cons.Revenue IFRS
Operating income¥242.1bn2025-01-01 → 2025-06-30Cons.Operating profit loss IFRS
Operating income¥126.3bn2024-01-01 → 2024-06-30Cons.Operating profit loss IFRS
Profit before tax¥226.3bn2025-01-01 → 2025-06-30Cons.Profit loss before tax IFRS
Profit before tax¥335.9bn2024-01-01 → 2024-12-31Cons.Profit loss before tax IFRS (5-year summary)
Profit before tax¥142.2bn2024-01-01 → 2024-06-30Cons.Profit loss before tax IFRS
Net income (owners)¥173.5bn2025-01-01 → 2025-06-30Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥343.1bn2024-01-01 → 2024-12-31Cons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)¥107.8bn2024-01-01 → 2024-06-30Cons.Profit loss attributable to owners of parent IFRS
Net income¥175.9bn2025-01-01 → 2025-06-30Cons.Profit loss IFRS
Net income¥110.6bn2024-01-01 → 2024-06-30Cons.Profit loss IFRS
Total assets¥3.79Tat 2025-06-30Cons.Assets IFRS
Total assets¥3.74Tat 2024-12-31Cons.Assets IFRS
Total assets¥3.66Tat 2024-06-30Cons.Total assets IFRS (5-year summary)
Total liabilities¥1.00Tat 2025-06-30Cons.Liabilities IFRS
Total liabilities¥961.1bnat 2024-12-31Cons.Liabilities IFRS
Net assets / equity¥2.79Tat 2025-06-30Cons.Equity IFRS
Net assets / equity¥2.78Tat 2024-12-31Cons.Equity IFRS
Net assets / equity¥2.67Tat 2024-06-30Cons.Equity IFRS
Net assets / equity¥2.44Tat 2023-12-31vCons.Equity IFRS
Equity (owners)¥2.72Tat 2025-06-30Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥2.73Tat 2024-12-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥2.62Tat 2024-06-30Cons.Equity attributable to owners of parent IFRS (5-year summary)
Cash & equivalents¥411.1bnat 2025-06-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥426.2bnat 2024-12-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥485.9bnat 2024-06-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥513.3bnat 2023-12-31vCons.Cash and cash equivalents IFRS
Operating cash flow¥212.7bn2025-01-01 → 2025-06-30Cons.Net cash provided by used in operating activities IFRS
Operating cash flow¥354.6bn2024-01-01 → 2024-12-31Cons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow¥133.0bn2024-01-01 → 2024-06-30Cons.Net cash provided by used in operating activities IFRS
Investing cash flow−¥130.9bn2025-01-01 → 2025-06-30Cons.Net cash provided by used in investing activities IFRS
Investing cash flow−¥265.8bn2024-01-01 → 2024-12-31Cons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow−¥159.2bn2024-01-01 → 2024-06-30Cons.Net cash provided by used in investing activities IFRS
Financing cash flow−¥85.4bn2025-01-01 → 2025-06-30Cons.Net cash provided by used in financing activities IFRS
Financing cash flow−¥189.4bn2024-01-01 → 2024-12-31Cons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow−¥26.2bn2024-01-01 → 2024-06-30Cons.Net cash provided by used in financing activities IFRS
EPS (basic)¥326.122025-01-01 → 2025-06-30Cons.Basic earnings loss per share IFRS
EPS (basic)¥633.762024-01-01 → 2024-12-31Cons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥198.612024-01-01 → 2024-06-30Cons.Basic earnings loss per share IFRS
Equity ratio71.8%at 2025-06-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio73.1%at 2024-12-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio71.6%at 2024-06-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 44
SegmentItemPeriodValue
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2025-01-01 → 2025-06-30¥56.7bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2025-01-01 → 2025-06-30¥55.1bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2025-01-01 → 2025-06-30¥1.6bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2025-01-01 → 2025-06-30¥5.0bn
Reconciling Itemsreconcilingrevenue2025-01-01 → 2025-06-30−¥1.7bn
Reconciling Itemsreconcilingrevenue intersegment2025-01-01 → 2025-06-30−¥1.7bn
Reconciling Itemsreconcilingsegment profit2025-01-01 → 2025-06-30−¥27.8bn
jpcrp040300-q2r_E21183-000Consumer Productsreportable segmentrevenue2025-01-01 → 2025-06-30¥15.8bn
jpcrp040300-q2r_E21183-000Consumer Productsreportable segmentrevenue external2025-01-01 → 2025-06-30¥15.8bn
jpcrp040300-q2r_E21183-000Consumer Productsreportable segmentrevenue intersegment2025-01-01 → 2025-06-30¥9m
jpcrp040300-q2r_E21183-000Consumer Productsreportable segmentsegment profit2025-01-01 → 2025-06-30¥12.9bn
jpcrp040300-q2r_E21183-000Nutraceuticalsreportable segmentrevenue2025-01-01 → 2025-06-30¥276.1bn
jpcrp040300-q2r_E21183-000Nutraceuticalsreportable segmentrevenue external2025-01-01 → 2025-06-30¥276.0bn
jpcrp040300-q2r_E21183-000Nutraceuticalsreportable segmentrevenue intersegment2025-01-01 → 2025-06-30¥19m
jpcrp040300-q2r_E21183-000Nutraceuticalsreportable segmentsegment profit2025-01-01 → 2025-06-30¥36.7bn
jpcrp040300-q2r_E21183-000Pharmaceuticalsreportable segmentrevenue2025-01-01 → 2025-06-30¥833.8bn
jpcrp040300-q2r_E21183-000Pharmaceuticalsreportable segmentrevenue external2025-01-01 → 2025-06-30¥833.8bn
jpcrp040300-q2r_E21183-000Pharmaceuticalsreportable segmentsegment profit2025-01-01 → 2025-06-30¥215.4bn
—segment totalrevenue2025-01-01 → 2025-06-30¥1.18T
—segment totalrevenue external2025-01-01 → 2025-06-30¥1.18T
—segment totalrevenue intersegment2025-01-01 → 2025-06-30¥1.7bn
—segment totalsegment profit2025-01-01 → 2025-06-30¥269.9bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2024-01-01 → 2024-06-30¥56.5bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2024-01-01 → 2024-06-30¥54.7bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2024-01-01 → 2024-06-30¥1.8bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2024-01-01 → 2024-06-30¥4.8bn
Reconciling Itemsreconcilingrevenue2024-01-01 → 2024-06-30−¥1.8bn
Reconciling Itemsreconcilingrevenue intersegment2024-01-01 → 2024-06-30−¥1.8bn
Reconciling Itemsreconcilingsegment profit2024-01-01 → 2024-06-30−¥24.2bn
jpcrp040300-q2r_E21183-000Consumer Productsreportable segmentrevenue2024-01-01 → 2024-06-30¥15.7bn
jpcrp040300-q2r_E21183-000Consumer Productsreportable segmentrevenue external2024-01-01 → 2024-06-30¥15.7bn
jpcrp040300-q2r_E21183-000Consumer Productsreportable segmentrevenue intersegment2024-01-01 → 2024-06-30¥3m
jpcrp040300-q2r_E21183-000Consumer Productsreportable segmentsegment profit2024-01-01 → 2024-06-30¥12.3bn
jpcrp040300-q2r_E21183-000Nutraceuticalsreportable segmentrevenue2024-01-01 → 2024-06-30¥271.8bn
jpcrp040300-q2r_E21183-000Nutraceuticalsreportable segmentrevenue external2024-01-01 → 2024-06-30¥271.8bn
jpcrp040300-q2r_E21183-000Nutraceuticalsreportable segmentrevenue intersegment2024-01-01 → 2024-06-30¥15m
jpcrp040300-q2r_E21183-000Nutraceuticalsreportable segmentsegment profit2024-01-01 → 2024-06-30¥37.3bn
jpcrp040300-q2r_E21183-000Pharmaceuticalsreportable segmentrevenue2024-01-01 → 2024-06-30¥766.7bn
jpcrp040300-q2r_E21183-000Pharmaceuticalsreportable segmentrevenue external2024-01-01 → 2024-06-30¥766.7bn
jpcrp040300-q2r_E21183-000Pharmaceuticalsreportable segmentsegment profit2024-01-01 → 2024-06-30¥96.0bn
—segment totalrevenue2024-01-01 → 2024-06-30¥1.11T
—segment totalrevenue external2024-01-01 → 2024-06-30¥1.11T
—segment totalrevenue intersegment2024-01-01 → 2024-06-30¥1.8bn
—segment totalsegment profit2024-01-01 → 2024-06-30¥150.5bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 782
ItemContextValueUnit
Transfer from other components of equity to retained earnings ss IFRSPrior1YTDDuration_CapitalSurplusIFRSMember－JPY
Transfer from other components of equity to retained earnings ss IFRSPrior1YTDDuration_TreasurySharesIFRSMember－JPY
Transfer from other components of equity to retained earnings ss IFRSPrior1YTDDuration_RetainedEarningsIFRSMember1059000000JPY
Transfer from other components of equity to retained earnings ss IFRSPrior1YTDDuration_RemeasurementsOfDefinedBenefitPlansIFRSMember-378000000JPY
Transfer from other components of equity to retained earnings ss IFRSPrior1YTDDuration_FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeIFRSMember-681000000JPY
Total transactions with owners IFRSPrior1YTDDuration_ShareCapitalIFRSMember－JPY
Total transactions with owners IFRSPrior1YTDDuration_CapitalSurplusIFRSMember-537000000JPY
Total transactions with owners IFRSPrior1YTDDuration_TreasurySharesIFRSMember1060000000JPY
Total transactions with owners IFRSPrior1YTDDuration_RetainedEarningsIFRSMember-31502000000JPY
Total transactions with owners IFRSPrior1YTDDuration_RemeasurementsOfDefinedBenefitPlansIFRSMember-378000000JPY
Total transactions with owners IFRSPrior1YTDDuration_FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeIFRSMember-681000000JPY
Equity IFRSPrior1QuarterInstant_ShareCapitalIFRSMember81690000000JPY
Equity IFRSPrior1QuarterInstant_CapitalSurplusIFRSMember505692000000JPY
Equity IFRSPrior1QuarterInstant_TreasurySharesIFRSMember-43608000000JPY
Equity IFRSPrior1QuarterInstant_RetainedEarningsIFRSMember1697511000000JPY
Equity IFRSPrior1QuarterInstant_RemeasurementsOfDefinedBenefitPlansIFRSMember－JPY
Equity IFRSPrior1QuarterInstant_FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeIFRSMember52179000000JPY
Equity IFRSPrior2YearInstant_ExchangeDifferencesOnTranslationOfForeignOperationsIFRSMember181815000000JPY
Equity IFRSPrior2YearInstant_EffectivePortionOfCashFlowHedgesIFRSMember43000000JPY
Equity IFRSPrior2YearInstant_OtherComponentsOfEquityIFRSMember229214000000JPY
Equity IFRSPrior2YearInstant_EquityAttributableToOwnersOfParentIFRSMember2393683000000JPY
Equity IFRSPrior2YearInstant_NonControllingInterestsIFRSMember42634000000JPY
Equity IFRSPrior2YearInstant2436317000000JPY
Profit loss IFRSPrior1YTDDuration_ExchangeDifferencesOnTranslationOfForeignOperationsIFRSMember－JPY
Profit loss IFRSPrior1YTDDuration_EffectivePortionOfCashFlowHedgesIFRSMember－JPY
Profit loss IFRSPrior1YTDDuration_OtherComponentsOfEquityIFRSMember－JPY
Profit loss IFRSPrior1YTDDuration_EquityAttributableToOwnersOfParentIFRSMember107795000000JPY
Profit loss IFRSPrior1YTDDuration_NonControllingInterestsIFRSMember2829000000JPY
Profit loss IFRSPrior1YTDDuration110625000000JPY
Other comprehensive income IFRSPrior1YTDDuration_ExchangeDifferencesOnTranslationOfForeignOperationsIFRSMember146568000000JPY
Other comprehensive income IFRSPrior1YTDDuration_EffectivePortionOfCashFlowHedgesIFRSMember-65000000JPY
Other comprehensive income IFRSPrior1YTDDuration_OtherComponentsOfEquityIFRSMember152386000000JPY
Other comprehensive income IFRSPrior1YTDDuration_EquityAttributableToOwnersOfParentIFRSMember152386000000JPY
Other comprehensive income IFRSPrior1YTDDuration_NonControllingInterestsIFRSMember1529000000JPY
Other comprehensive income IFRSPrior1YTDDuration153915000000JPY
Comprehensive income IFRSPrior1YTDDuration_ExchangeDifferencesOnTranslationOfForeignOperationsIFRSMember146568000000JPY
Comprehensive income IFRSPrior1YTDDuration_EffectivePortionOfCashFlowHedgesIFRSMember-65000000JPY
Comprehensive income IFRSPrior1YTDDuration_OtherComponentsOfEquityIFRSMember152386000000JPY
Comprehensive income IFRSPrior1YTDDuration_EquityAttributableToOwnersOfParentIFRSMember260182000000JPY
Comprehensive income IFRSPrior1YTDDuration_NonControllingInterestsIFRSMember4358000000JPY
Comprehensive income IFRSPrior1YTDDuration264541000000JPY
Purchase of treasury shares ss IFRSPrior1YTDDuration_ExchangeDifferencesOnTranslationOfForeignOperationsIFRSMember－JPY
Purchase of treasury shares ss IFRSPrior1YTDDuration_EffectivePortionOfCashFlowHedgesIFRSMember－JPY
Purchase of treasury shares ss IFRSPrior1YTDDuration_OtherComponentsOfEquityIFRSMember－JPY
Purchase of treasury shares ss IFRSPrior1YTDDuration_EquityAttributableToOwnersOfParentIFRSMember-1000000JPY
Purchase of treasury shares ss IFRSPrior1YTDDuration_NonControllingInterestsIFRSMember－JPY
Purchase of treasury shares ss IFRSPrior1YTDDuration-1000000JPY
Dividends ss IFRSPrior1YTDDuration_ExchangeDifferencesOnTranslationOfForeignOperationsIFRSMember－JPY
Dividends ss IFRSPrior1YTDDuration_EffectivePortionOfCashFlowHedgesIFRSMember－JPY
Dividends ss IFRSPrior1YTDDuration_OtherComponentsOfEquityIFRSMember－JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2024-12-31pass rounding
balance sheet identityconsolidated 2025-06-30pass
dei present pass
period resolution pass
statement vs summary · net income attributable to parentconsolidated 2024-01-01/2024-06-30pass
statement vs summary · net income attributable to parentconsolidated 2025-01-01/2025-06-30pass
statement vs summary · operating cash flowconsolidated 2024-01-01/2024-06-30pass
statement vs summary · operating cash flowconsolidated 2025-01-01/2025-06-30pass
statement vs summary · revenueconsolidated 2024-01-01/2024-06-30pass
statement vs summary · revenueconsolidated 2025-01-01/2025-06-30pass
statement vs summary · total assetsconsolidated 2024-12-31pass
statement vs summary · total assetsconsolidated 2025-06-30pass